Breakthrough Device Designation: What It Gets You and What It Doesn't

May 28, 2026

Key Takeaways

• Breakthrough Device Designation (BDD) accelerates your FDA engagement, but it does not lower the evidentiary standard for safety and effectiveness under 21 CFR 860.7.

• The real strategic value of BDD is earlier, more collaborative FDA input on your regulatory strategy and testing required to show safety and effectiveness.

• Companies that mistake BDD for regulatory leniency often face late-stage data requests they could have anticipated with a stronger upfront strategy.

The Misconception That Is Costing Programs

When a medical device company receives Breakthrough Device Designation, the reaction is often, understandably, relief. FDA has confirmed your device addresses a serious or life-threatening condition and offers more effective treatment or diagnosis than current options. The designation feels like validation.

The most common strategic error we see in early-stage programs is treating BDD as evidence that FDA has softened the evidentiary requirements. It has not. The standard under 21 CFR 860.7 — valid scientific evidence sufficient to support a finding of reasonable assurance of safety and effectiveness — applies to your PMA with the same force it would without the designation.

What the Breakthrough Device Program Actually Does

The Breakthrough Devices Program was established under Section 515B of the Federal Food, Drug, and Cosmetic Act, enacted as part of the 21st Century Cures Act. FDA's December 2018 guidance, Breakthrough Devices Program, describes the program's scope and operational expectations in detail.

What the program does is modify how FDA engages with you, not what FDA requires of you.

BDD companies receive:

• Priority review: Your submission (Pre-Submissions or Premarket Submissions) move to the front of the review queue, compressing total review time.

• More frequent, interactive communication: FDA commits to more direct engagement throughout development and review, including access to senior staff and real-time exchange of information.

• Early and iterative feedback on clinical and non-clinical study design: Engage FDA on your non-clinical and clinical protocols, primary endpoints, and evidence thresholds before studies are underway.

The practical implication here is significant: none of these benefits reduce what your data must show. They change how quickly you can align with FDA on what your data needs to show.

What BDD Does Not Do

This is where the misconception creates real risk.

BDD does not:

• Lower the evidentiary threshold. The standard for reasonable assurance of safety and effectiveness does not have a "breakthrough" modifier. Your device is held to the same evidentiary standard as every other PMA.

• Guarantee FDA will accept your clinical protocol. Early engagement is an opportunity to align, not a mechanism for automatic agreement. FDA can and will push back on endpoints, study design, and control arms regardless of designation.

• Protect you from Additional Information (AI) requests. If your submission does not meet the standard at review, FDA will request additional information.

• Substitute for a regulatory strategy. BDD is a process acceleration tool. It does nothing for a program that has not yet defined its evidence framework, benefit-risk rationale, or submission strategy.

The Strategic Value of BDD — When It Is Used Correctly

BDD is genuinely powerful. The programs that benefit most from the designation share a common trait: they enter the program with a rigorous regulatory strategy already in place and use FDA engagement to pressure-test and refine it.

If your next step after designation is drafting a clinical protocol from scratch without a defined primary endpoint grounded in a literature-based evidence framework, you are not ready to use the designation effectively. Interactive communication only works when you have concrete, substantive proposals for FDA to engage with.

The companies that convert BDD into faster time to approval front-load their regulatory thinking: evidence strategy before study design, pre-defined endpoints before Pre-Submission, and a clear benefit-risk framework before the pivotal IDE application.

Building a BDD Strategy That Holds Up

If you have received Breakthrough Device Designation here is how to approach the work:

• Define your evidentiary framework before your first BDD meeting with FDA. Know what valid scientific evidence looks like for your device category. Review the Breakthrough Devices Program guidance alongside any device-type-specific FDA guidance relevant to your technology. Do not enter an interactive review without a proposed evidence plan.

• Use Q-Submissions strategically. The Q-Submission program, described in FDA's guidance Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program, gives BDD companies a mechanism to obtain written FDA feedback on specific questions. Use this to lock in alignment on clinical endpoints and acceptance criteria, not just to introduce your device.

• Document every piece of FDA feedback and act on it. Every response you receive in an interactive review should be incorporated into your regulatory strategy. Treat it as a signal of FDA's expectations at review, not as optional input.

BDD accelerates the path. Your regulatory strategy determines whether you are ready to go.

Questions to Ask About Your Program

• Have you defined, in writing, with reference to FDA guidance, the specific evidentiary standard your PMA will need to meet before designing your pivotal study?

• If you have received BDD, do you have a Q-Submission plan that leverages interactive engagement to lock in alignment on clinical endpoints and acceptance criteria?

• Is your evidence strategy documented and sequenced, from clinical framework through submission, in a way that accounts for what BDD can and cannot provide?

• If FDA issued an Additional Information request on your current evidence plan, would you know how to respond?

If you would like a strategic perspective on how BDD fits into your regulatory plan, we are happy to think through it with you. Reach out to the FCG team at folioconsultinggroup.com.